drugset / Trial / NCT03418727

Dry Eye Disease Study With Brimonidine

NCT03418727

Phase 2 Completed 84 enrolled Ocugen
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).

Timeline

Start
2017-09-06
Primary completion
2018-03-29
Completion
2018-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.2 % Other

Indications